As the lesion progresses to adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma, mutations or overexpression in the epidermal growth factor receptor (EGFR) pathway also begin to show their significance.18, 19. This evidence concerns the gene EGFR and adenocarcinoma in situ.